View Article

  • Xanthine oxidase inhibitor for the management of gout by dietary supplements and medicinally important plants

  • Photo Muskan Prasad* Photo Rajat Das Photo Jyochhana Priya Mohanty

  • Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, East Sikkim – 737136, India.

Abstract

Hyperuricemia, caused by elevated xanthine oxidase (XO) activity, which generates reactive oxygen species and catalyzes the final steps of purine breakdown to uric acid, is a characteristic of gout, a frequent inflammatory arthritis. The cornerstone of modern pharmacological treatment is synthetic XO inhibitors, such as febuxostat and allopurinol, which effectively lower blood urate levels and reduce gout flare-ups. Nevertheless, these medications have disadvantages, such as organ damage, hypersensitivity, and irregular patient compliance. Dietary supplements and medicinal plants are gaining popularity as complementary or alternative XO inhibitors due to their superior safety profiles and additional antioxidant and anti-inflammatory qualities. The discovery and optimization of both synthetic and natural XO inhibitors have been accelerated by contemporary computational techniques, such as network pharmacology, molecular docking, QSAR modelling, and machine learning, which allow the identification of multitarget candidates with better safety and efficacy profiles. However, there are still obstacles in the way of converting plant-based and dietary interventions into standardized, clinically proven treatments, such as the requirement for strong randomized trials, heterogeneity in phytochemical composition, and scarcity of pharmacokinetic and toxicological data. To improve bioavailability and patient adherence in gout treatment, future strategies include sophisticated delivery methods, logical combination regimens, and personalized medicine tactics. This review emphasizes the potential of combining natural and conventional XO inhibitors for the safe and effective treatment of gout. However, it also emphasizes the necessity of thorough scientific confirmation to fully realize their therapeutic benefits.

Keywords

Hyperuricemia, Xanthine oxidase (XO), Gout treatment, Natural XO inhibitors, Computational pharmacology

Introduction

A prevalent inflammatory arthropathy is gout. Research indicates that the frequency is 2.7% in Australia and 1.7% in New Zealand, with greater rates in M?ori and islander groups. GOUT and hyperurecemia are on the rise, according to the National Health and Nutrition Examination Survey (NHANES) in the United States and studies carried out in China, the United Kingdom, and New Zealand (1). The rate-limiting step in human purine catabolism is the oxidation of hypoxanthine to xanthine and xanthine to uric acid, which is catalyzed by an enzyme called xanthine oxidase (XO), which contains molybdenum (2). Both contemporary non-purine drugs, like febuxostat, and conventional XO inhibitors, like allopurinol, effectively reduce blood uric acid levels and the frequency of gout flare-ups; nevertheless, they are limited by response variability, hypersensitivity reactions, and cardiovascular safety concerns (3). A review of natural substances with XO inhibitory effect found that several flavonoids, stilbenes, alkaloids, and phenolic acids have IC50 values in the low micromolar range, indicating true drug-lead potential for antigout therapy (4). A crucial method for examining how complex herbal medicines or plant extracts affect various gout-related targets, including renal urate transporters, inflammatory mediators, and XO, is network pharmacology (5). When combined with traditional urate-lowering medications, a number of supplements can somewhat reduce serum urate and flare frequency, according to a recent systematic review and meta-analysis of dietary supplements for hyperuricemia and gout. However, heterogeneity and poor trial quality are still issues (6). Cherries, celery, parsley, berries, tea, coffee, and other edible foods and botanicals contain these bioactive compounds, which may change uric acid metabolism through diet (7).

  1. Xanthine oxidase and its inhibitor
    1. Biochemistry of xanthine oxidase: Role in uric acid formation.

The final stage of purine metabolism in humans is catalysed by an enzyme known as xanthine oxidase (XO), which converts hypoxanthine to xanthine and subsequently xanthine to uric acid (8). The main organs that remove uric acid are the kidneys and intestines; excessive uric acid levels, or hyperuricemia, are essential for the development of gout (9).  XO catalysis produces reactive oxygen species (ROS), such as superoxide anions, which are connected to oxidative stress and vascular damage associated with gout and related illnesses (10).

      1. Biochemical Pathway of Uric Acid Formation:
        1. Purine Breakdown: Through a sequence of enzymatic events involving nucleotidases and nucleosidases, endogenous and dietary purines (adenine and guanine) are broken down into hypoxanthine and xanthine(11).
        2. Hypoxanthine to Xanthine: Using molecular oxygen as the electron acceptor, xanthine oxidase catalyses the conversion of hypoxanthine to xanthine.  One byproduct that is produced is hydrogen peroxide (H2O2) (12).
        3. The enzyme oxidises xanthine to uric acid, which results in the production of H2O?.  This stage is important because uric acid is poorly soluble and can crystallise in joints and tissues, resulting in gout (13).
        4. Reactive Oxygen Species (ROS): Xanthine oxidase generates a range of ROS, such as superoxide anions and hydrogen peroxide, throughout both processes. ROS can cause oxidative stress and tissue damage (14).
      2. Enzyme Mechanism and Regulation
        1. Catalytic Mechanism: Uric acid is produced by moving electrons from xanthine to oxygen with the aid of a molybdenum cofactor present in the active site of xanthine oxidase (15).
      3. Regulation: Xanthine oxidase activity is significantly impacted by substrate availability, enzyme expression, and post-translational modifications.  The enzyme is primarily present in humans as xanthine oxidase, while other mammals may possibly have it as xanthine dehydrogenase (16).
      4. Rate-Limiting Step: Xanthine oxidase is a promising therapeutic target for gout and hyperuricemia since it is believed to be a rate-limiting enzyme in the creation of uric acid (17).
      1. Clinical Implications:
        1. Hyperuricemia and Gout: High uric acid levels brought on by increased xanthine oxidase activity are the main cause of hyperuricemia, which is a major risk factor for gout. The buildup of monosodium urate crystals in joints, which causes pain and inflammation, is the hallmark of gout (18).
      2. Therapeutic Target: Xanthine oxidase inhibitors, including allopurinol and febuxostat, reduce uric acid production and prevent gout attacks by competitively blocking the enzyme (19).
    2. Mechanism of xanthine oxidase inhibition

Xanthine oxidase (XO) inhibitors reduce the synthesis of uric acid by binding to the active site or adjacent regions of the enzyme and blocking the entry of hypoxanthine and xanthine (20). The molybdenum cofactor (Mo-co) in the active site is necessary for XO catalytic activity. It interacts with inhibitors either directly or indirectly to halt oxidation reactions (21). Allopurinol, a purine analogue that acts as a competitive inhibitor, is transformed by XO into oxypurinol, which binds Mo-co firmly and causes reversible inhibition (22). Febuxostat is a potent, non-competitive, non-purine inhibitor that attaches to the substrate channel and Mo-co to stop electron transport and the generation of ROS (23). A strong, non-competitive, non-purine inhibitor, febuxostat binds to the substrate channel and Mo-co to prevent electron transport and ROS production (24).These naturally occurring inhibitors often cause reversible competitive inhibition by occupying the substrate binding site (25). Important XO amino acids, like Arg880 and Glu802, stabilise inhibitor binding, which is required for the inhibition of enzyme activity, as shown by molecular docking and kinetic studies (26). When inhibitors attach to XO and result in secondary structural alterations, like modifications to α-helices and β-sheets, catalytic efficiency is reduced (26). Inhibition efficiently reduces uric acid production by interfering with the electron flux required for the oxidation of xanthine and hypoxanthine (27). As a result, XO inhibitors lessen hyperuricemia and oxidative stress, two significant factors in the development of gout (28).

    1. Clinical xanthine oxidase inhibitors: synthetic drugs

Clinical xanthine oxidase inhibitors, such as febuxostat and allopurinol, are significant drugs used to treat hyperuricemia and gout by lowering serum uric acid levels by blocking xanthine oxidase (29).

      1. Allopurinol: Mechanism and Profile
        1.  Allopurinol functions as a competitive inhibitor of xanthine oxidase, reducing the conversion of xanthine and hypoxanthine to uric acid. This dissolves gout tophi and decreases serum urate concentrations (30).
        2.  It has been well studied and proven to be successful in reducing oxidative stress, improving endothelial function, and lowering the chance of developing renal disease (31).
        3.  Allopurinol has been licensed by the FDA to treat tumour lysis syndrome, gout, and recurrent calcium nephrolithiasis. Clinical applications for autoimmune, cardiovascular, and renal conditions are also possible (32).
        4.  Because the drug is primarily metabolised to oxypurinol in the liver and removed by the kidneys, patients with renal impairment must adjust their dosage (33).
      2. Febuxostat: Mechanism and Profile
        1.  In individuals who are intolerant to allopurinol, febuxostat, a non-purine, selective xanthine oxidase inhibitor, significantly inhibits the enzyme (34).
        2.  Clinical studies demonstrate that it is superior to allopurinol in achieving target uric acid levels below 6.0 mg/dL, particularly at doses of 40–120 mg/day, with rapid and sustained uric acid reductions and a decreased chance of gout flare-ups (35).
        3.  Even in those with mild-to-moderate renal or hepatic impairment, febuxostat is effective independent of age or gender (36).
        4.  Both short-term and long-term trials have shown that febuxostat has a reasonable safety profile; adverse effects include headache, arthralgia, mild elevation of liver enzymes, and potential cardiovascular issues, all of which necessitate additional monitoring (37).
    2. Advances in new synthetic inhibitors of xanthine oxidase

Structural changes in synthetic scaffolds, such as thiazolidine-2-thione derivatives with phenyl-sulfonamide groups, have yielded inhibitors with 2.5 times greater potency than allopurinol and a mixed-type inhibitory mechanism, suggesting novel binding interactions with XO (38):

      1. Molecular docking and virtual screening

Hierarchical virtual screening procedures that integrate ligand-based and structure-based techniques have been widely used to uncover novel XO in order to successfully identify hits and find new chemotypes.is derived from extensive chemical libraries (39). Molecular docking and molecular dynamics (MD) simulations clarify the binding modalities and contact stability of potential XO inhibitors, validating computational studies and predicting inhibition mechanisms (40). Using modern spectrum fusion techniques, enzyme assays, and large-scale chromatographic separation improves the accuracy and dependability of natural product inhibitor screening (41).

      1. Quantitative Structure-Activity Relationship (QSAR) and Machine Learning (ML) Modelling

Machine learning (ML) techniques like support vector regression (SVR), random forest (RF), and XGBoost have expedited the screening process by producing QSAR models that accurately forecast the inhibitory activity of XO of synthetic and natural drugs (42). Hybrid AI models, which steer molecular optimisations for hit-to-lead development, improve the interpretability and reliability of predictions by Using descriptors based on ligands and structures (43). XO inhibitory peptides have been effectively identified and optimized using ML-based peptide prediction models, which exhibit good generalization to various peptide lengths and structures(44).

      1. Advanced Simulations and Deep Learning

Long molecular dynamics trajectories and deep learning methods, including neural relational inference, provide novel information for rational drug design by revealing allosteric inhibitory mechanisms and protein structural alterations brought on by XO inhibitors (45).

  1. Gout treatment with xanthine oxidase inhibitors

 

Table 1: Allopurinol versus febuxostat clinical outcomes and safety

Aspect

Allopurinol

Febuxostat

Effectiveness in lowering blood levels of uric acid

A common first-line drug that successfully reduces serum urate; occasionally less effective, particularly at lower dosages(46).

More effective overall, reaching goal urate levels more quickly and in a greater proportion of patients(47).

Effectiveness in managing gout

long-term efficacy in preventing tophi regression and gout flare-ups (48).

Demonstrated greater effectiveness in a number of trials, especially in individuals with allopurinol intolerance or renal impairment (49).

Renal results

It may slow the advancement of kidney disease in people with hyperuricemia; with dose adjustments, it is safe for CKD (50).

enhances the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD); it is safe but requires close observation(51).

Cardiovascular consequences

Generally safe for the heart; some data points to a neutral or beneficial impact on the heart(52).

Although early studies raised some concerns, more recent data shows that the majority of patients have not had a notable increase in cardiovascular events (53).

Safety overview

Side effects include hypersensitivity reactions (rare but serious), rash, gastrointestinal symptoms; requires careful patient selection and monitoring(54)?.

Cardiovascular safety is being continuously assessed; modest elevations in liver enzymes have been documented; generally well tolerated(55).

Adherence and dosage titration

must be gradually titrated to reduce the possibility of adverse effects and increase effectiveness (56).

Additionally, titration and monitoring are essential, especially for patients with comorbidities (57).

Practical application and patient inclination

It is most commonly recommended worldwide because of its affordability and proven efficacy (58).

Although it could be more expensive, elderly or allopurinol-intolerant individuals often take it (59).

 

    1.       The challenges and negative consequences of traditional therapies

Treatment intolerance and coexisting diseases, such as renal impairment and cardiovascular illness, are issues with traditional gout therapy that limit pharmaceutical options and complicate management.(60). In many gout patients, gastrointestinal sensitivity to uricosuric drugs and first-line xanthine oxidase inhibitors (like allopurinol) leads to poor adherence (61). Due to resistance or contraindications to common urate-lowering medications, older patients or those with many comorbidities frequently require alternative therapy, making care challenging(62). Steroid dependence, which raises the risk of fractures and cardiovascular issues, can result from refractory gout and a lack of therapeutic alternatives (63). Xanthine oxidase inhibitor side effects include hypersensitivity responses, liver problems, and kidney problems, which call for careful dosage titration and monitoring(64). Anti-inflammatory medications such NSAIDs or low-dose colchicine must be prescribed together with xanthine oxidase inhibitor therapy in order to prevent acute gout attacks (65).

  1. Management of gout using dietary supplies

Reducing inflammatory flare-ups or marginally lowering blood urate levels are the two main objectives of dietary supplements for gout therapy. Usually, these supplements are taken in conjunction with conventional urate-lowering medication rather than in place of it.  Due to the sometimes weak to moderate quality of the evidence, these supplements should be carefully integrated into guidelines-based gout management (66).

    1. Role of Nutrition and Dietary Supplements in the Management of Hyperuricemia

Dietary management, which emphasises reducing purine-rich foods and alcohol while increasing the intake of low-fat dairy, fruits, vegetables, and water to help lower serum uric acid levels, is a crucial part of controlling hyperuricemia(67). Evidence indicates that a healthy diet can somewhat lower serum urate levels and may lessen the incidence of gout flare-ups, while its effects are less obvious than those of pharmacological urate-lowering therapy(68).

    1. Evidence for Specific Supplements

Meta-analyses have verified the supplement's minor uricosuric impact, and randomised controlled trials have shown that consuming 500 mg of vitamin C significantly lowers blood uric acid levels (69). Higher dietary vitamin C intake is linked to a lower risk of incident gout, according to prospective cohort studies in men, supporting its possible adjunctive role (70). The anti-inflammatory and antioxidant benefits of cherries and cherry products, which are linked to lower blood uric acid levels and a lower frequency of gout flare-ups, have been shown in both observational and interventional studies (71). According to pilot studies, drinking tart cherry juice concentrate for at least four months can lessen the frequency of acute gout flare-ups. This is probably because it suppresses inflammatory pathways rather than lowering urate levels directly (72). The majority of studies only show modest decreases in blood uric acid, despite the scant and conflicting clinical evidence suggesting the possible mild urate-lowering and anti-inflammatory benefits of omega-3 fatty acids(73). Systematic reviews and guidelines emphasise that these supplements should not be used in place of traditional urate-lowering medications in the treatment of hyperuricemia, even though they may provide an extra benefit (74).

 

Table 2: Xanthine Oxidase Inhibitor Sources from Food and Supplements

 

Category

Examples

Primary Source/Compound(s)

Dietary Source/Description

Isolated Compound(s)

The mode of action (MoA)

Reference(s)

Food

Legumes (soybeans, chickpeas), nuts (walnuts, almonds), cereals (brown rice, oats), fruits (apple, grape)

Phytic acid, Flavonoids (kaempferol, quercetin, myricetin), Phenolics

Typical foods with antioxidant and anti-inflammatory qualities

Phytic acid, Kaempferol, Quercetin, Myricetin

Competitive or non-competitive XO inhibition

(75)

Beverages

Green tea, black tea, coffee, red wine, herbal infusions (hibiscus, chamomile)

Flavonoids (quercetin, myricetin), Chlorogenic acid, Resveratrol in red wine

Widely consumed antioxidant-rich drinks with bioactive compounds

Quercetin, Myricetin, Chlorogenic acid, Resveratrol

Competitive XO inhibition

(76),(77)

Dietary Supplements

Herbal extracts (Ginkgo biloba, Curcuma longa, Morinda citrifolia), flavonoid supplements, turmeric, grape seed extract

Flavonoids, curcuminoids, phenolic acids

Concentrated extracts and nutraceuticals marketed for inflammation and gout relief

Quercetin, Curcumin, Resveratrol, Coumarin

Competitive XO inhibition

(78),(79),(80)

Table 3: Plant-Based Inhibitors of Xanthine Oxidase

Scientific name

Plant part

Isolated compound

The mode of action

References

Salvia spinosa L.

Whole aerial part

Luteolin, Apigenin

Competitive XO inhibition

(81)

Anthemis palestina Boiss.

Whole plant

Quercetin

Competitive XO inhibition

(82)

Chrysanthemum coronarium L.

Flower

Chlorogenic acid, Apigenin

Competitive XO inhibition

(83)

Achillea biebersteinii Afan.

Whole plant

Luteolin

Competitive XO inhibition

(84)

Momordica charantia

Pulp

Coumarin, Quercetin

Competitive XO inhibition

(85)

Cissus quadrangularis

Whole plant

Quercetin, Kaempferol

Competitive XO inhibition

(86)

Boerhavia diffusa

Whole plant

Boeravinone B, Quercetin

Competitive XO inhibition

(87)

Ailanthus altissima

Flowers

 

Suppression of Xanthine Oxidase

(88)

Ginkgo biloba L.

Leaves

Kaempferol, Quercetin

Competitive XO inhibition

(89)
 
  1. Xanthine oxidase inhibiting – medicinal plants

Many studies have been conducted on the potential of medicinal herbs with xanthine oxidase (XO) inhibitory activity to cure gout and hyperuricemia. The uric acid-producing enzyme XO can be inhibited by a number of traditional botanicals, according to ethnobotanical, preclinical, and clinical studies (90).

    1. Ethnobotanical Approaches

Gout has traditionally been treated with herbs, especially in regions where herbal medicine is common.  Plants with anti-inflammatory and uric acid-lowering qualities, such as Rosmarinus officinalis, Ginkgo biloba, and Artemisia herba-alba, are sometimes passed down through the generations to relieve joint discomfort and swelling associated with gout (91).

    1.  Important Plants and Their Processes

Artemisia herba-alba: The significant XO inhibiting activity of its methanolic extract is caused by the flavonoid and phenolic components of Artemisia herba-alba, which also reinforce its antioxidant properties  (92).

Ginkgo biloba: Research has demonstrated that Ginkgo biloba leaf extract (GBE) suppresses XO activity in both in vitro and animal models.  Active flavonoids like quercetin and kaempferol reduce oxidative stress and uric acid production by competitively inhibiting XO (93).

Rosmarinus officinalis: Rosmarinic acid and rosemary diterpenes stop the production of XO and superoxide anions.  Its antioxidant qualities further promote its usage in gout treatment (94).

    1. Clinical and preclinical research on therapeutic plants

Preclinical studies have consistently shown that extracts from these plants reduce serum uric acid levels and inhibit XO activity in animal models of hyperuricemia and gout.  The growing amount of clinical evidence supporting Ginkgo biloba and Rosmarinus officinalis is bolstered by studies demonstrating decreases in uric acid levels and inflammatory markers in human patients.(95).

    1. Safety and Toxicity Profiles

Despite the fact that most of these plants are believed to be safe at therapeutic dosages, caution must be exercised due to possible herb-drug interactions and differences in extract composition. Clinical research has documented a few instances of hepatotoxicity at high doses or continuous use, along with mild side effects like gastrointestinal distress (96).

  1. Comparative analysis
    1. Comparative effectiveness of synthetic XO inhibitors vs. dietary/plant remedies

In terms of proven urate-lowering efficacy and guideline-based gout treatment, synthetic xanthine oxidase (XO) inhibitors such as allopurinol, febuxostat, and topiroxostat remain unquestionably superior, whereas plant/dietary solutions are best positioned as adjuncts with potential but less solid data.  Nonetheless, several XO inhibitors that come from foods and plants have potent biochemical activity in addition to extra anti-inflammatory and antioxidant properties, which makes them appealing choices for longer-term, safer therapies or nutraceuticals (97,98).

      1. According to comprehensive randomised trials and recommendations, synthetic xanthine oxidase inhibitors (allopurinol, febuxostat, and topiroxostat) are the best drugs for treating gout and reducing urate levels (99).
      2. Compared to synthetic drugs, plant-based xanthine oxidase inhibitors such as flavonoids and alkaloids from medicinal plants show significant in vitro and in vivo XO inhibition but lack substantial clinical validation (100).
      3. While dietary components like green tea polyphenols and tart cherries show strong XO inhibition and may lower the incidence of gout flare-ups, their therapeutic efficacy as stand-alone therapy is limited (101).
      4. Although nutritional therapy and plant supplements are intriguing, more clinical research is required. Synthetic inhibitors are preferred because to their potent potency and defined safety and dosage guidelines (102).
  2. Future perspectives and research directions

Future prospects for treating gout using xanthine oxidase inhibitors (XOIs) mostly depend on the creation of safer, more effective, and customised therapy strategies.  Furthermore, there is increasing interest in employing dietary supplements and medicinal herbs as extra or replacement sources of XOIs (103).

    1.  Recent advancements in xanthine oxidase suppression
      1. The primary recent developments in xanthine oxidase inhibition include the development of novel synthetic and natural inhibitors, complex drug design methods, and the application of computational and machine learning technologies for rapid screening and optimisation (104).
      2. In addition to conventional purine analogues, various molecular scaffolds from pharmaceutical and dietary sources—such as flavonoids, phenolic acids, stilbenes, alkaloids, polysaccharides, and polypeptides—are being studied(105).
      3. To overcome the drawbacks of current therapeutic drugs like febuxostat and allopurinol, highly selective and multifunctional inhibitors are increasingly being developed via molecular hybridisation and fragment-based drug design (FBDD) (106). 
      4. Computational methods such as machine learning, Quantitative Structure-Activity Relationship (QSAR) modelling, network pharmacology, and molecular docking are mostly used to identify efficient xanthine oxidase inhibitors from both synthetic and natural libraries (107).
      5. These techniques enable rapid screening and bioactivity prediction, which expedites the search for multitarget inhibitors with improved safety and efficacy profiles (108).
      6. Natural and food-derived xanthine oxidase inhibitors like hesperetin, notopterol, and cnidimol B are becoming more and more well-known because of their demonstrated efficacy and favourable safety profiles in experimental settings (109).
      7. These substances are being investigated for their potential as gout adjuvants or alternative therapies due to their low toxicity and structural variation (110).
      8. Another new trend is the development of personalised medical methods that use genetic biomarkers to tailor care to each patient's distinct profile (111).
      9. Combination therapy, which combines xanthine oxidase inhibitors with other urate-lowering drugs, is being investigated to improve control in refractory cases, and new fixed-dose combination therapies are starting to be used in clinical settings (112). Innovative drug delivery techniques that can enhance therapy outcomes and patient adherence for both synthetic and plant-based inhibitors are being investigated, such as mucoadhesive gels and tailored formulations (113).
    2.  Possibilities and challenges in the creation of plant-based therapies

Recent years have seen extensive research on the promise and problems of creating plant-based gout therapies, underscoring the field's potential (114). Plant-based therapies offer a safer and more sustainable substitute for conventional medications due to the strong xanthine oxidase inhibitory activity and anti-inflammatory effects of various phytochemicals, such as flavonoids and polyphenolic compounds, which supports their potential as adjunct or alternative treatments for gout (115). However, a number of challenges impede the advancement of these therapies, such as the cost and difficulty of separating active ingredients, unclear pharmacophores, and the need for more pharmacokinetic, pharmacodynamic, and toxicological research to ensure clinical safety and efficacy (116). There is a growing need for comprehensive preclinical and clinical research that supports an evidence-based approach to incorporate plant-based treatments in modern healthcare in order to fully understand their efficacy and safety (117). Advanced drug delivery techniques, like mucoadhesive gels and nanoparticles, are being researched to boost patient adherence and bioavailability in order to further enhance the therapeutic potential of plant-based inhibitors (118). Although plant-based therapies present encouraging opportunities for safer and more comfortable gout therapy, their successful application in clinical settings depends on resolving these concerns through in-depth scientific research (119).

CONCLUSION

The significant potential of plant-based xanthine oxidase inhibitors (XOIs) and dietary supplements as safe, natural alternatives to or supplements for conventional gout therapy.  These natural substances' urate-lowering, anti-inflammatory, and antioxidant qualities offer promising therapeutic benefits that can successfully manage gout with minimal adverse effects. The therapeutic application of these plant-derived inhibitors is hampered by a number of factors, despite encouraging in vitro and in vivo results. The absence of comprehensive pharmacokinetic and toxicological data, variations in phytochemical composition brought on by processing and environmental factors, and the challenge of separating and characterising active compounds from plants are some of the primary barriers. Such difficulties necessitate substantial clinical trials, comprehensive mechanistic investigations, and exact standardisation to guarantee their safe and effective usage in humans.  Additionally, the use of modern computational techniques like molecular docking and network pharmacology speeds up the discovery and improvement of potent plant-based XOIs, enhancing their development prospects. The bioavailability and therapeutic outcomes of these natural inhibitors may be further improved by innovative drug delivery techniques, such as mucoadhesive and customised formulations, which address the issues of low solubility and patient compliance.  The future of gout treatment is probably going to be personalised medicine approaches that mix synthetic and plant-based inhibitors tailored to each patient's profile for best effectiveness. In conclusion, even though plant-based XOIs show a lot of potential as part of an integrated strategy to gout therapy, systematic research is required to get over current scientific and clinical barriers in order to turn this potential into useful, reasonably priced medications. This multidisciplinary effort will assist develop safer, more patient-friendly therapy options globally and expand the pharmacopoeia for gout.

  1. Authors’ contribution: M.P: Writing original draft, conceptualization and reviewing. R.D: Reviewing, Conceptualization, editing, visualization and Validation. J.P.M.: Reviewing, Conceptualization and Visualization. All Authors reviewed properly and approved for final version of manuscript.
  2. Conflict of interest: The author declares no conflict of interest regarding the publication of the manuscript.
  3. Acknowledgement: The authors would like to thank Himalayan Pharmacy Institute for Library search and Digital support.

REFERENCES

  1. Lin Z, Gupta JK, Maqbool M, Kumar K, Sharma A, Wahi N. The Therapeutic Management of Chemical and Herbal Medications on Uric Acid Levels and Gout: Modern and Traditional Wisdom. Pharmaceuticals. 2024 Nov;17(11):1507.
  2. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol-Endocrinol Metab. 2020 Nov;319(5):E827–34.
  3. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  4. Zhou S, Huang G. The Inhibitory Activity of Natural Products to Xanthine Oxidase. Chem Biodivers. 2023 May;20(5):e202300005.
  5. Qian Y, Yin J, Ni J, Chen X, Shen Y. A Network Pharmacology Method Combined with Molecular Docking Verification to Explore the Therapeutic Mechanisms Underlying Simiao Pill Herbal Medicine against Hyperuricemia. BioMed Res Int. 2023 Feb 9;2023:2507683.
  6. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  7. The inhibition activity on tyrosinase, xanthine oxidase, and lipase of Musa balbisiana parts grown in Vietnam - Hoang - 2024 - Food Science & Nutrition - Wiley Online Library [Internet]. [cited 2025 Nov 22]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.4364
  8. Aziz N, Jamil RT. Biochemistry, Xanthine Oxidase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK545245/
  9. Kosti? DA, Dimitrijevi? DS, Stojanovi? GS, Pali? IR, ?or?evi? AS, Ickovski JD. Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition. J Chem. 2015;2015(1):294858.
  10. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  11. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016 June 15;213:8–14.
  12. Ali N, Taher A, Islam N, Sarna NZ, Islam F. Evaluation of the relationship between xanthine oxidase activity and metabolic syndrome in a population group in Bangladesh. Sci Rep. 2024 Sept 2;14(1):20380.
  13. Chen C, Lü JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit Int Med J Exp Clin Res. 2016 July 17;22:2501–12.
  14. Ali N, Taher A, Islam N, Sarna NZ, Islam F. Evaluation of the relationship between xanthine oxidase activity and metabolic syndrome in a population group in Bangladesh. Sci Rep. 2024 Sept 2;14(1):20380.
  15. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021;8(2):405–16.
  16. Bortolotti M, Polito L, Battelli MG, Bolognesi A. Xanthine oxidoreductase: One enzyme for multiple physiological tasks. Redox Biol. 2021 May 1;41:101882.
  17. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol-Endocrinol Metab. 2020 Nov;319(5):E827–34.
  18. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  19. Alghamdi AA, Althumali JS, Almalki MMM, Almasoudi AS, Almuntashiri AH, Almuntashiri AH, et al. An Overview on the Role of Xanthine Oxidase Inhibitors in Gout Management. Arch Pharm Pract. 2021;12(3–2021):94–9.
  20. Wang Y, Zhang G, Pan J, Gong D. Novel Insights into the Inhibitory Mechanism of Kaempferol on Xanthine Oxidase. J Agric Food Chem. 2015 Jan 21;63(2):526–34.
  21. de Brito Monteiro L, Archambault AS, Starchuk LF, Alcazar A, Oh JH, Dubland JA, et al. Inhibition of xanthine oxidoreductase with febuxostat, but not allopurinol, prevents inflammasome assembly and IL-1β release. Life Sci Alliance. 2025 May 21;8(8):e202403191.
  22. Xanthine Oxidase Inhibitor - an overview | ScienceDirect Topics [Internet]. [cited 2025 Nov 22]. Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/xanthine-oxidase-inhibitor
  23. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice. Sci Rep. 2014 Apr 1;4(1):4554.
  24. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 22];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  25. Xue H, Xu M, Gong D, Zhang G. Mechanism of flavonoids inhibiting xanthine oxidase and alleviating hyperuricemia from structure–activity relationship and animal experiments: A review. Food Front. 2023;4(4):1643–65.
  26. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021 Jan 26;8(2):405–16.
  27. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021 Jan 26;8(2):405–16.
  28. Evaluation of Xanthine Oxidase Inhibitors Febuxostat and Allopurinol on Kidney Dysfunction and Histological Damage in Two?Kidney, One?Clip (2K1C) Rats - Shuvo - 2025 - Scientifica - Wiley Online Library [Internet]. [cited 2025 Nov 22]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1155/sci5/7932075
  29. Qurie A, Preuss CV, Musa R. Allopurinol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK499942/
  30. Allopurinol [Internet]. [cited 2025 Nov 24]. Available from: https://go.drugbank.com/drugs/DB00437
  31. Alenezi AA, Sattar MAAA, Ibrahim IM. Effect of allopurinol and other xanthine oxidase inhibitors on oxidative stress in Alzheimer’s disease: A systematic review and meta-analysis (2015–2025). Int J Health Sci. 2025 July 18;9(S1):355–77.
  32. Allopurinol - an overview | ScienceDirect Topics [Internet]. [cited 2025 Nov 24]. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/allopurinol
  33. Stamp LK, Chapman PT, Palmer SC. Allopurinol and kidney function: An update. Joint Bone Spine. 2016 Jan 1;83(1):19–24.
  34. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  35. Chen J, Zhang Y, Wang Y, Chen L. Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis. Ren Fail. 47(1):2470478.
  36. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  37. Yang TL, Leu HB, Lin SJ, Horng JL, Shih CM. Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study. J Formos Med Assoc [Internet]. 2025 June 2 [cited 2025 Nov 24]; Available from: https://www.sciencedirect.com/science/article/pii/S0929664625002700
  38. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 24];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  39. Nguyen AH, Do AT, Linh NN, Pham MQ, Ngo ST, Le TKD. Searching for potential xanthine oxidase inhibitors from Vietnamese herb plants via computational studies. Comput Biol Chem. 2026 Feb 1;120:108763.
  40. Zhang Y, Ban C, Su D, Liu Y, Zhou S, Fan J. Xanthine oxidase inhibitors: Virtual screening and mechanism of inhibition studies. Int J Biol Macromol. 2024 Nov;281(Pt 1):136281.
  41. Meng R, Zhou Y, Liu X, Fei L, Shi D, Li S, et al. Rapid discovery of xanthine oxidase inhibitors from Cimicifugae Rhizoma with bioactivity evaluation. J Mol Struct. 2026 Feb 15;1352:144468.
  42. Yang X, Qiu H, Zhang Y, Zhang P. Quantitative structure–activity relationship study of amide derivatives as xanthine oxidase inhibitors using machine learning. Front Pharmacol [Internet]. 2023 June 29 [cited 2025 Nov 24];14. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1227536/full
  43. Klambauer G, Hochreiter S, Rarey M. Machine Learning in Drug Discovery. J Chem Inf Model. 2019 Mar 25;59(3):945–6.
  44. Chen Q, Ge Y, He X, Li S, Fang Z, Li C, et al. Virtual-screening of xanthine oxidase inhibitory peptides: Inhibition mechanisms and prediction of activity using machine-learning. Food Chem. 2024 Dec 1;460(Pt 3):140741.
  45. He Y, Liu K, Cao F, Song R, Liu J, Zhang Y, et al. Using deep learning and molecular dynamics simulations to unravel the regulation mechanism of peptides as noncompetitive inhibitor of xanthine oxidase. Sci Rep. 2024 Jan 2;14(1):174.
  46. Castrejon I, Toledano E, Rosario MP, Loza E, Pérez-Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015 July;35(7):1127–37.
  47. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  48. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct 1;45(2):174–83.
  49. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  50. Sharbaf FG, Bakhtiari E, Faghihi T, Assadi F. Efficacy and Safety of Allopurinol on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis. J Pediatr Pharmacol Ther JPPT. 2024 Aug;29(4):359–67.
  51. Waheed YA, Yang F, Liu J, Almayahe S, Selvam KKM, Wang D, et al. Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study. Front Nephrol [Internet]. 2025 Mar 26 [cited 2025 Nov 24];5. Available from: https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2025.1526182/full
  52. Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022 Oct 8;400(10359):1195–205.
  53. Guan X, Zhang S, Liu J, Wu F, Zhou L, Liu Y, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis. Front Pharmacol [Internet]. 2022 Sept 30 [cited 2025 Nov 24];13. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.998441/full
  54. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct 1;45(2):174–83.
  55. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  56. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012 Aug;64(8):2529–36.
  57. Conley B, Bunzli S, Bullen J, O’Brien P, Persaud J, Gunatillake T, et al. What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines. BMC Rheumatol. 2023 June 15;7(1):15.
  58. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD006077.
  59. Kelly VM, Krishnan E. Febuxostat for the treatment of hyperuricemia in patients with gout. Int J Clin Rheumatol. 2011 Oct;6(5):485–93.
  60. Chong LY, Nandagudi A. OA07 The therapeutic dead-end in gout: a case of failed conventional and uricosuric therapies. Rheumatol Adv Pract. 2025 Nov 1;9(Supplement_1):rkaf111.007.
  61. Crittenden DB, Kim HN, Fisher MC, Goldfarb DS, Pillinger MH. New and emerging therapies for gout. Clin Investig. 2011 Nov;1(11):1563–75.
  62. Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging. 2014 Nov;31(11):777–86.
  63. Afzal M, Rednam M, Gujarathi R, Widrich J. Gout. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK546606/
  64. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  65. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  66. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  67. Gout: diagnosis and management. London: National Institute for Health and Care Excellence; 2022.
  68. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  69. Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005 June;52(6):1843–7.
  70. Choi HK, Gao X, Curhan G. Vitamin C Intake and the Risk of Gout in Men – A Prospective Study. Arch Intern Med. 2009 Mar 9;169(5):502–7.
  71. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D, Choi HK. Cherry Consumption and the Risk of Recurrent Gout Attacks. Arthritis Rheum. 2012 Dec;64(12):4004–11.
  72. Shi E, Wang R, Xu L, Wang H, Li M, Guo K, et al. Tart cherry extract alleviates gouty inflammatory response by down-regulating NF-κB signaling pathway. Food Biosci. 2025 Sept 1;71:107253.
  73. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  74. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  75. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  76. Lin S, Zhang G, Liao Y, Pan J, Gong D. Dietary Flavonoids as Xanthine Oxidase Inhibitors: Structure–Affinity and Structure–Activity Relationships. J Agric Food Chem. 2015 Sept 9;63(35):7784–94.
  77. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 26];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  78. Orhan IE, Deniz FSS. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? Curr Pharm Des. 2021;27(2):143–58.
  79. Sui Y, Shi J, Cai S, Xiong T, Xie B, Sun Z, et al. Metabolites of Procyanidins From Litchi Chinensis Pericarp With Xanthine Oxidase Inhibitory Effect and Antioxidant Activity. Front Nutr [Internet]. 2021 Sept 21 [cited 2025 Nov 26];8. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.676346/full
  80. Mehmood A, Ishaq M, Zhao L, Safdar B, Rehman A ur, Munir M, et al. Natural compounds with xanthine oxidase inhibitory activity: A review. Chem Biol Drug Des. 2019;93(4):387–418.
  81. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  82. Benedict F, Shallangwa GA, Goya N, Umar A, Ibrahim ZY, Chandra A. Design and screening of novel geniposide derivatives as xanthine oxidase inhibitors for hyperuricemia treatment using QSAR, Molecular docking, Molecular dynamics simulation, ADMET, and DFT Approaches. Lett Drug Des Discov. 2025 Sept 1;22(9):100153.
  83. Lin S, Zhang G, Liao Y, Pan J, Gong D. Dietary Flavonoids as Xanthine Oxidase Inhibitors: Structure–Affinity and Structure–Activity Relationships. J Agric Food Chem. 2015 Sept 9;63(35):7784–94.
  84. Kuwabara M, Nakai M, Sumita Y, Iwanaga Y, Ae R, Kodama T, et al. Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome. Front Pharmacol [Internet]. 2024 Jan 8 [cited 2025 Nov 26];14. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1289386/full
  85. Tey ZT, Loh KE, Tan SP, Yuan C, Tejo BA, Ismail IS, et al. Xanthine oxidase inhibitory activity by flavonoids from Chrysanthemum morifolium: in vitro and in silico insights. Phytochem Lett. 2024 Dec 1;64:68–78.
  86. Sun ZG, Wu KX, Ullah I, Zhu HL. Recent Advances in Xanthine Oxidase Inhibitors. Mini Rev Med Chem. 2024;24(12):1177–86.
  87. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  88. Nguyen DK, Liu TW, Hsu SJ, Huynh QDT, Thi Duong TL, Chu MH, et al. Xanthine oxidase inhibition study of isolated secondary metabolites from Dolichandrone spathacea (Bignoniaceae): In vitro and in silico approach. Saudi Pharm J. 2024 Apr 1;32(4):101980.
  89. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct;278(Pt 3):134832.
  90. Le UQ. The review on medicinal herbs in the treatment of gout through xanthine oxidase inhibitory activity: Call for more research strategy in the future. J Appl Pharm Sci. 2024 Apr 5;14,(4):001–13.
  91. Hudaib MM, Tawaha KA, Mohammad MK, Assaf AM, Issa AY, Alali FQ, et al. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants. Pharmacogn Mag. 2011;7(28):320–4.
  92. Hudaib MM, Tawaha KA, Mohammad MK, Assaf AM, Issa AY, Alali FQ, et al. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants. Pharmacogn Mag. 2011;7(28):320–4.
  93. Chen W, Liu Y, Wei M, Shi L, Wu Y, Liu Z, et al. Studies on effect of Ginkgo biloba L. leaves in acute gout with hyperuricemia model rats by using UPLC-ESI-Q-TOF/MS metabolomic approach. 2017 Sept 5 [cited 2025 Nov 26]; Available from: https://pubs.rsc.org/en/content/articlehtml/2017/ra/c7ra08519b
  94. Gonçalves C, Fernandes D, Silva I, Mateus V. Potential Anti-Inflammatory Effect of Rosmarinus officinalis in Preclinical In Vivo Models of Inflammation. Molecules. 2022 Jan 18;27(3):609.
  95. Gonçalves C, Fernandes D, Silva I, Mateus V. Potential Anti-Inflammatory Effect of Rosmarinus officinalis in Preclinical In Vivo Models of Inflammation. Molecules. 2022 Jan 18;27(3):609.
  96. Jalali J, Ghasemzadeh Rahbardar M. Rosemary: A Promising Therapeutic Agent in Alleviating Nephrotoxicity. J Food Biochem. 2025;2025(1):5519628.
  97. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  98. Scanu A, Luisetto R, Ramonda R, Spinella P, Sfriso P, Galozzi P, et al. Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout. Curr Issues Mol Biol. 2022 Oct 25;44(11):5173–90.
  99. Claus LW, Auten ME, Saseen JJ, Billups SJ. Guideline adherence of xanthine oxidase inhibitor utilization to treat gout in primary care. J Manag Care Spec Pharm. 2025 Sept;31(9):922–7.
  100. Yu D, Du J, He P, Wang N, Li L, Liu Y, et al. Identification of natural xanthine oxidase inhibitors: Virtual screening, anti-xanthine oxidase activity, and interaction mechanism. Int J Biol Macromol. 2024 Feb 1;259:129286.
  101. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  102. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  103. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  104. Yu D, Du J, He P, Wang N, Li L, Liu Y, et al. Identification of natural xanthine oxidase inhibitors: Virtual screening, anti-xanthine oxidase activity, and interaction mechanism. Int J Biol Macromol. 2024 Feb 1;259:129286.
  105. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  106. Singh A, Singh K, Sharma A, Kaur K, Chadha R, Singh Bedi PM. Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials. RSC Med Chem. 14(11):2155–91.
  107. Machine-learning and simulation identify food-derived xanthine oxidase inhibitors with in-vitro activity | Scientific Reports [Internet]. [cited 2025 Nov 26]. Available from: https://www.nature.com/articles/s41598-025-25624-x
  108. Discovery of Natural Multitarget Xanthine Oxidase Inhibitors for Therapeutic Hyperuricemia Using Virtual Screening, Network Pharmacology and in vitro Experimental Verification | Semantic Scholar [Internet]. [cited 2025 Nov 26]. Available from: https://www.semanticscholar.org/paper/Discovery-of-Natural-Multitarget-Xanthine-Oxidase-Cao-Ma/69ae7c5cdba514d25e4dc7863b0a6587c87d7082
  109. Cao L, Ma B, Yi B, Liu Y, Sun J. Discovery of Natural Multitarget Xanthine Oxidase Inhibitors for Therapeutic Hyperuricemia Using Virtual Screening, Network Pharmacology and in vitro Experimental Verification. ChemistrySelect. 2023 Aug 11;8(30):e202301939.
  110. Orhan IE, Deniz FSS. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? Curr Pharm Des. 2021;27(2):143–58.
  111. Global Perspectives on Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Growth: 2025-2033 Insights [Internet]. 2025 [cited 2025 Nov 26]. Available from: https://www.datainsightsmarket.com/reports/xanthine-oxidase-inhibitors-for-the-treatment-of-hyperuricemia-304508
  112. Kumar N, Kaur K, Kaur N, Singh E, Bedi PMS. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023). Bioorganic Chem. 2024 Feb 1;143:107042.
  113. Mehmood A, Ishaq M, Zhao L, Safdar B, Rehman AU, Munir M, et al. Natural compounds with xanthine oxidase inhibitory activity: A review. Chem Biol Drug Des. 2019 Apr;93(4):387–418.
  114. Wu J, Alhamoud Y, Lv S, Feng F, Wang J. Beneficial properties and mechanisms of natural phytochemicals to combat and prevent hyperuricemia and gout. Trends Food Sci Technol. 2023 Aug 1;138:355–69.
  115. Kumari S, Maurya RK. Therapeutic Potential of Natural Products in Gout Management. Int J Res Publ Rev. 2025 Mar;6(3):4457–63.
  116. Exploring the potential of some medicinal plants for the treatment of gouty arthritis | Journal of Population Therapeutics and Clinical Pharmacology [Internet]. [cited 2025 Nov 26]. Available from: https://www.jptcp.com/index.php/jptcp/article/view/7622
  117. Frontiers | Chromene flavanones from Dalea boliviana as xanthine oxidase inhibitors: in vitro biological evaluation and molecular docking studies [Internet]. [cited 2025 Nov 26]. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1576390/full
  118. Kumar N, Kaur K, Kaur N, Singh E, Bedi PMS. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023). Bioorganic Chem. 2024 Feb 1;143:107042.
  119. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.

Reference

  1. Lin Z, Gupta JK, Maqbool M, Kumar K, Sharma A, Wahi N. The Therapeutic Management of Chemical and Herbal Medications on Uric Acid Levels and Gout: Modern and Traditional Wisdom. Pharmaceuticals. 2024 Nov;17(11):1507.
  2. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol-Endocrinol Metab. 2020 Nov;319(5):E827–34.
  3. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  4. Zhou S, Huang G. The Inhibitory Activity of Natural Products to Xanthine Oxidase. Chem Biodivers. 2023 May;20(5):e202300005.
  5. Qian Y, Yin J, Ni J, Chen X, Shen Y. A Network Pharmacology Method Combined with Molecular Docking Verification to Explore the Therapeutic Mechanisms Underlying Simiao Pill Herbal Medicine against Hyperuricemia. BioMed Res Int. 2023 Feb 9;2023:2507683.
  6. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  7. The inhibition activity on tyrosinase, xanthine oxidase, and lipase of Musa balbisiana parts grown in Vietnam - Hoang - 2024 - Food Science & Nutrition - Wiley Online Library [Internet]. [cited 2025 Nov 22]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.4364
  8. Aziz N, Jamil RT. Biochemistry, Xanthine Oxidase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK545245/
  9. Kosti? DA, Dimitrijevi? DS, Stojanovi? GS, Pali? IR, ?or?evi? AS, Ickovski JD. Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition. J Chem. 2015;2015(1):294858.
  10. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  11. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016 June 15;213:8–14.
  12. Ali N, Taher A, Islam N, Sarna NZ, Islam F. Evaluation of the relationship between xanthine oxidase activity and metabolic syndrome in a population group in Bangladesh. Sci Rep. 2024 Sept 2;14(1):20380.
  13. Chen C, Lü JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit Int Med J Exp Clin Res. 2016 July 17;22:2501–12.
  14. Ali N, Taher A, Islam N, Sarna NZ, Islam F. Evaluation of the relationship between xanthine oxidase activity and metabolic syndrome in a population group in Bangladesh. Sci Rep. 2024 Sept 2;14(1):20380.
  15. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021;8(2):405–16.
  16. Bortolotti M, Polito L, Battelli MG, Bolognesi A. Xanthine oxidoreductase: One enzyme for multiple physiological tasks. Redox Biol. 2021 May 1;41:101882.
  17. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol-Endocrinol Metab. 2020 Nov;319(5):E827–34.
  18. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  19. Alghamdi AA, Althumali JS, Almalki MMM, Almasoudi AS, Almuntashiri AH, Almuntashiri AH, et al. An Overview on the Role of Xanthine Oxidase Inhibitors in Gout Management. Arch Pharm Pract. 2021;12(3–2021):94–9.
  20. Wang Y, Zhang G, Pan J, Gong D. Novel Insights into the Inhibitory Mechanism of Kaempferol on Xanthine Oxidase. J Agric Food Chem. 2015 Jan 21;63(2):526–34.
  21. de Brito Monteiro L, Archambault AS, Starchuk LF, Alcazar A, Oh JH, Dubland JA, et al. Inhibition of xanthine oxidoreductase with febuxostat, but not allopurinol, prevents inflammasome assembly and IL-1β release. Life Sci Alliance. 2025 May 21;8(8):e202403191.
  22. Xanthine Oxidase Inhibitor - an overview | ScienceDirect Topics [Internet]. [cited 2025 Nov 22]. Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/xanthine-oxidase-inhibitor
  23. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice. Sci Rep. 2014 Apr 1;4(1):4554.
  24. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 22];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  25. Xue H, Xu M, Gong D, Zhang G. Mechanism of flavonoids inhibiting xanthine oxidase and alleviating hyperuricemia from structure–activity relationship and animal experiments: A review. Food Front. 2023;4(4):1643–65.
  26. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021 Jan 26;8(2):405–16.
  27. Ribeiro PMG, Fernandes HS, Maia LB, Sousa SF, Moura JJG, Cerqueira NMFSA. The complete catalytic mechanism of xanthine oxidase: a computational study. Inorg Chem Front. 2021 Jan 26;8(2):405–16.
  28. Evaluation of Xanthine Oxidase Inhibitors Febuxostat and Allopurinol on Kidney Dysfunction and Histological Damage in Two?Kidney, One?Clip (2K1C) Rats - Shuvo - 2025 - Scientifica - Wiley Online Library [Internet]. [cited 2025 Nov 22]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1155/sci5/7932075
  29. Qurie A, Preuss CV, Musa R. Allopurinol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK499942/
  30. Allopurinol [Internet]. [cited 2025 Nov 24]. Available from: https://go.drugbank.com/drugs/DB00437
  31. Alenezi AA, Sattar MAAA, Ibrahim IM. Effect of allopurinol and other xanthine oxidase inhibitors on oxidative stress in Alzheimer’s disease: A systematic review and meta-analysis (2015–2025). Int J Health Sci. 2025 July 18;9(S1):355–77.
  32. Allopurinol - an overview | ScienceDirect Topics [Internet]. [cited 2025 Nov 24]. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/allopurinol
  33. Stamp LK, Chapman PT, Palmer SC. Allopurinol and kidney function: An update. Joint Bone Spine. 2016 Jan 1;83(1):19–24.
  34. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  35. Chen J, Zhang Y, Wang Y, Chen L. Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis. Ren Fail. 47(1):2470478.
  36. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  37. Yang TL, Leu HB, Lin SJ, Horng JL, Shih CM. Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study. J Formos Med Assoc [Internet]. 2025 June 2 [cited 2025 Nov 24]; Available from: https://www.sciencedirect.com/science/article/pii/S0929664625002700
  38. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 24];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  39. Nguyen AH, Do AT, Linh NN, Pham MQ, Ngo ST, Le TKD. Searching for potential xanthine oxidase inhibitors from Vietnamese herb plants via computational studies. Comput Biol Chem. 2026 Feb 1;120:108763.
  40. Zhang Y, Ban C, Su D, Liu Y, Zhou S, Fan J. Xanthine oxidase inhibitors: Virtual screening and mechanism of inhibition studies. Int J Biol Macromol. 2024 Nov;281(Pt 1):136281.
  41. Meng R, Zhou Y, Liu X, Fei L, Shi D, Li S, et al. Rapid discovery of xanthine oxidase inhibitors from Cimicifugae Rhizoma with bioactivity evaluation. J Mol Struct. 2026 Feb 15;1352:144468.
  42. Yang X, Qiu H, Zhang Y, Zhang P. Quantitative structure–activity relationship study of amide derivatives as xanthine oxidase inhibitors using machine learning. Front Pharmacol [Internet]. 2023 June 29 [cited 2025 Nov 24];14. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1227536/full
  43. Klambauer G, Hochreiter S, Rarey M. Machine Learning in Drug Discovery. J Chem Inf Model. 2019 Mar 25;59(3):945–6.
  44. Chen Q, Ge Y, He X, Li S, Fang Z, Li C, et al. Virtual-screening of xanthine oxidase inhibitory peptides: Inhibition mechanisms and prediction of activity using machine-learning. Food Chem. 2024 Dec 1;460(Pt 3):140741.
  45. He Y, Liu K, Cao F, Song R, Liu J, Zhang Y, et al. Using deep learning and molecular dynamics simulations to unravel the regulation mechanism of peptides as noncompetitive inhibitor of xanthine oxidase. Sci Rep. 2024 Jan 2;14(1):174.
  46. Castrejon I, Toledano E, Rosario MP, Loza E, Pérez-Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015 July;35(7):1127–37.
  47. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  48. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct 1;45(2):174–83.
  49. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  50. Sharbaf FG, Bakhtiari E, Faghihi T, Assadi F. Efficacy and Safety of Allopurinol on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis. J Pediatr Pharmacol Ther JPPT. 2024 Aug;29(4):359–67.
  51. Waheed YA, Yang F, Liu J, Almayahe S, Selvam KKM, Wang D, et al. Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study. Front Nephrol [Internet]. 2025 Mar 26 [cited 2025 Nov 24];5. Available from: https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2025.1526182/full
  52. Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022 Oct 8;400(10359):1195–205.
  53. Guan X, Zhang S, Liu J, Wu F, Zhou L, Liu Y, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis. Front Pharmacol [Internet]. 2022 Sept 30 [cited 2025 Nov 24];13. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.998441/full
  54. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct 1;45(2):174–83.
  55. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Ther Adv Musculoskelet Dis. 2011 Oct;3(5):245–53.
  56. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012 Aug;64(8):2529–36.
  57. Conley B, Bunzli S, Bullen J, O’Brien P, Persaud J, Gunatillake T, et al. What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines. BMC Rheumatol. 2023 June 15;7(1):15.
  58. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD006077.
  59. Kelly VM, Krishnan E. Febuxostat for the treatment of hyperuricemia in patients with gout. Int J Clin Rheumatol. 2011 Oct;6(5):485–93.
  60. Chong LY, Nandagudi A. OA07 The therapeutic dead-end in gout: a case of failed conventional and uricosuric therapies. Rheumatol Adv Pract. 2025 Nov 1;9(Supplement_1):rkaf111.007.
  61. Crittenden DB, Kim HN, Fisher MC, Goldfarb DS, Pillinger MH. New and emerging therapies for gout. Clin Investig. 2011 Nov;1(11):1563–75.
  62. Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging. 2014 Nov;31(11):777–86.
  63. Afzal M, Rednam M, Gujarathi R, Widrich J. Gout. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK546606/
  64. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  65. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  66. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  67. Gout: diagnosis and management. London: National Institute for Health and Care Excellence; 2022.
  68. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  69. Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005 June;52(6):1843–7.
  70. Choi HK, Gao X, Curhan G. Vitamin C Intake and the Risk of Gout in Men – A Prospective Study. Arch Intern Med. 2009 Mar 9;169(5):502–7.
  71. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D, Choi HK. Cherry Consumption and the Risk of Recurrent Gout Attacks. Arthritis Rheum. 2012 Dec;64(12):4004–11.
  72. Shi E, Wang R, Xu L, Wang H, Li M, Guo K, et al. Tart cherry extract alleviates gouty inflammatory response by down-regulating NF-κB signaling pathway. Food Biosci. 2025 Sept 1;71:107253.
  73. Ye G, Liu C, Zheng X, Fang J, Xie C, Liu M, et al. The effectiveness and safety of specific dietary supplements in modulating uric acid levels, oxidative stress, and lipid metabolism in patients: a network meta-analysis of 13 interventions. Nutr Metab. 2025 July 23;22:80.
  74. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  75. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  76. Lin S, Zhang G, Liao Y, Pan J, Gong D. Dietary Flavonoids as Xanthine Oxidase Inhibitors: Structure–Affinity and Structure–Activity Relationships. J Agric Food Chem. 2015 Sept 9;63(35):7784–94.
  77. Mehmood A, Li J, Rehman AU, Kobun R, Llah IU, Khan I, et al. Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds. Front Nutr [Internet]. 2022 Sept 20 [cited 2025 Nov 26];9. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.966557/full
  78. Orhan IE, Deniz FSS. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? Curr Pharm Des. 2021;27(2):143–58.
  79. Sui Y, Shi J, Cai S, Xiong T, Xie B, Sun Z, et al. Metabolites of Procyanidins From Litchi Chinensis Pericarp With Xanthine Oxidase Inhibitory Effect and Antioxidant Activity. Front Nutr [Internet]. 2021 Sept 21 [cited 2025 Nov 26];8. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.676346/full
  80. Mehmood A, Ishaq M, Zhao L, Safdar B, Rehman A ur, Munir M, et al. Natural compounds with xanthine oxidase inhibitory activity: A review. Chem Biol Drug Des. 2019;93(4):387–418.
  81. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022 Aug 26;14(17):3525.
  82. Benedict F, Shallangwa GA, Goya N, Umar A, Ibrahim ZY, Chandra A. Design and screening of novel geniposide derivatives as xanthine oxidase inhibitors for hyperuricemia treatment using QSAR, Molecular docking, Molecular dynamics simulation, ADMET, and DFT Approaches. Lett Drug Des Discov. 2025 Sept 1;22(9):100153.
  83. Lin S, Zhang G, Liao Y, Pan J, Gong D. Dietary Flavonoids as Xanthine Oxidase Inhibitors: Structure–Affinity and Structure–Activity Relationships. J Agric Food Chem. 2015 Sept 9;63(35):7784–94.
  84. Kuwabara M, Nakai M, Sumita Y, Iwanaga Y, Ae R, Kodama T, et al. Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome. Front Pharmacol [Internet]. 2024 Jan 8 [cited 2025 Nov 26];14. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1289386/full
  85. Tey ZT, Loh KE, Tan SP, Yuan C, Tejo BA, Ismail IS, et al. Xanthine oxidase inhibitory activity by flavonoids from Chrysanthemum morifolium: in vitro and in silico insights. Phytochem Lett. 2024 Dec 1;64:68–78.
  86. Sun ZG, Wu KX, Ullah I, Zhu HL. Recent Advances in Xanthine Oxidase Inhibitors. Mini Rev Med Chem. 2024;24(12):1177–86.
  87. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  88. Nguyen DK, Liu TW, Hsu SJ, Huynh QDT, Thi Duong TL, Chu MH, et al. Xanthine oxidase inhibition study of isolated secondary metabolites from Dolichandrone spathacea (Bignoniaceae): In vitro and in silico approach. Saudi Pharm J. 2024 Apr 1;32(4):101980.
  89. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct;278(Pt 3):134832.
  90. Le UQ. The review on medicinal herbs in the treatment of gout through xanthine oxidase inhibitory activity: Call for more research strategy in the future. J Appl Pharm Sci. 2024 Apr 5;14,(4):001–13.
  91. Hudaib MM, Tawaha KA, Mohammad MK, Assaf AM, Issa AY, Alali FQ, et al. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants. Pharmacogn Mag. 2011;7(28):320–4.
  92. Hudaib MM, Tawaha KA, Mohammad MK, Assaf AM, Issa AY, Alali FQ, et al. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants. Pharmacogn Mag. 2011;7(28):320–4.
  93. Chen W, Liu Y, Wei M, Shi L, Wu Y, Liu Z, et al. Studies on effect of Ginkgo biloba L. leaves in acute gout with hyperuricemia model rats by using UPLC-ESI-Q-TOF/MS metabolomic approach. 2017 Sept 5 [cited 2025 Nov 26]; Available from: https://pubs.rsc.org/en/content/articlehtml/2017/ra/c7ra08519b
  94. Gonçalves C, Fernandes D, Silva I, Mateus V. Potential Anti-Inflammatory Effect of Rosmarinus officinalis in Preclinical In Vivo Models of Inflammation. Molecules. 2022 Jan 18;27(3):609.
  95. Gonçalves C, Fernandes D, Silva I, Mateus V. Potential Anti-Inflammatory Effect of Rosmarinus officinalis in Preclinical In Vivo Models of Inflammation. Molecules. 2022 Jan 18;27(3):609.
  96. Jalali J, Ghasemzadeh Rahbardar M. Rosemary: A Promising Therapeutic Agent in Alleviating Nephrotoxicity. J Food Biochem. 2025;2025(1):5519628.
  97. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021 Apr;30(2):122–30.
  98. Scanu A, Luisetto R, Ramonda R, Spinella P, Sfriso P, Galozzi P, et al. Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout. Curr Issues Mol Biol. 2022 Oct 25;44(11):5173–90.
  99. Claus LW, Auten ME, Saseen JJ, Billups SJ. Guideline adherence of xanthine oxidase inhibitor utilization to treat gout in primary care. J Manag Care Spec Pharm. 2025 Sept;31(9):922–7.
  100. Yu D, Du J, He P, Wang N, Li L, Liu Y, et al. Identification of natural xanthine oxidase inhibitors: Virtual screening, anti-xanthine oxidase activity, and interaction mechanism. Int J Biol Macromol. 2024 Feb 1;259:129286.
  101. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  102. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  103. Antoniolli G, de Moraes GR, da Costa RPN, de Campos GAR, Coelho F. Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. Arch Pharm (Weinheim). 2025 Aug;358(8):e70079.
  104. Yu D, Du J, He P, Wang N, Li L, Liu Y, et al. Identification of natural xanthine oxidase inhibitors: Virtual screening, anti-xanthine oxidase activity, and interaction mechanism. Int J Biol Macromol. 2024 Feb 1;259:129286.
  105. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.
  106. Singh A, Singh K, Sharma A, Kaur K, Chadha R, Singh Bedi PM. Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials. RSC Med Chem. 14(11):2155–91.
  107. Machine-learning and simulation identify food-derived xanthine oxidase inhibitors with in-vitro activity | Scientific Reports [Internet]. [cited 2025 Nov 26]. Available from: https://www.nature.com/articles/s41598-025-25624-x
  108. Discovery of Natural Multitarget Xanthine Oxidase Inhibitors for Therapeutic Hyperuricemia Using Virtual Screening, Network Pharmacology and in vitro Experimental Verification | Semantic Scholar [Internet]. [cited 2025 Nov 26]. Available from: https://www.semanticscholar.org/paper/Discovery-of-Natural-Multitarget-Xanthine-Oxidase-Cao-Ma/69ae7c5cdba514d25e4dc7863b0a6587c87d7082
  109. Cao L, Ma B, Yi B, Liu Y, Sun J. Discovery of Natural Multitarget Xanthine Oxidase Inhibitors for Therapeutic Hyperuricemia Using Virtual Screening, Network Pharmacology and in vitro Experimental Verification. ChemistrySelect. 2023 Aug 11;8(30):e202301939.
  110. Orhan IE, Deniz FSS. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? Curr Pharm Des. 2021;27(2):143–58.
  111. Global Perspectives on Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Growth: 2025-2033 Insights [Internet]. 2025 [cited 2025 Nov 26]. Available from: https://www.datainsightsmarket.com/reports/xanthine-oxidase-inhibitors-for-the-treatment-of-hyperuricemia-304508
  112. Kumar N, Kaur K, Kaur N, Singh E, Bedi PMS. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023). Bioorganic Chem. 2024 Feb 1;143:107042.
  113. Mehmood A, Ishaq M, Zhao L, Safdar B, Rehman AU, Munir M, et al. Natural compounds with xanthine oxidase inhibitory activity: A review. Chem Biol Drug Des. 2019 Apr;93(4):387–418.
  114. Wu J, Alhamoud Y, Lv S, Feng F, Wang J. Beneficial properties and mechanisms of natural phytochemicals to combat and prevent hyperuricemia and gout. Trends Food Sci Technol. 2023 Aug 1;138:355–69.
  115. Kumari S, Maurya RK. Therapeutic Potential of Natural Products in Gout Management. Int J Res Publ Rev. 2025 Mar;6(3):4457–63.
  116. Exploring the potential of some medicinal plants for the treatment of gouty arthritis | Journal of Population Therapeutics and Clinical Pharmacology [Internet]. [cited 2025 Nov 26]. Available from: https://www.jptcp.com/index.php/jptcp/article/view/7622
  117. Frontiers | Chromene flavanones from Dalea boliviana as xanthine oxidase inhibitors: in vitro biological evaluation and molecular docking studies [Internet]. [cited 2025 Nov 26]. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1576390/full
  118. Kumar N, Kaur K, Kaur N, Singh E, Bedi PMS. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023). Bioorganic Chem. 2024 Feb 1;143:107042.
  119. Ullah Z, Yue P, Mao G, Zhang M, Liu P, Wu X, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024 Oct 1;278:134832.

Photo
Muskan Prasad
Corresponding author

Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, East Sikkim – 737136, India.

Photo
Rajat Das
Co-author

Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, East Sikkim – 737136, India.

Photo
Jyochhana Priya Mohanty
Co-author

Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, East Sikkim – 737136, India

Muskan Prasad, Rajat Das, Jyochhana Priya Mohanty, Xanthine Oxidase Inhibitor for The Management of Gout by Dietary Supplements and Medicinally Important Plants, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 2783-2801, https://doi.org/10.5281/zenodo.19629094

More related articles
A Comprehensive Review on Pharmacist Contributions...
Dr. Sphurthymitra, P. Naga Sruthi, ...
Promoting Green Chemistry in Analysis: An Assessme...
Umaparvathy S., Karunya B., Sakthivel S., Manikandan R., Gokula S...
A Review of the Latest Breakthroughs in Cancer Tre...
Vikas Rathod, Swapnil Kale, Sneha Kanase , Shraddha Shelke, Adity...
View more
A Systematic review of B-caryophyllene and Piperine as Multitarget Phytochemical...
Kavita Gaisamudre, Prakash Sarwade, Aditya Mishra, Gaurav Chaudhary, Omprakash Swami, Akash Verma, S...
Computer Simulation and Molecular Docking Studies of Natural Compoundschrysin, M...
Silpa Vijayan, Dr. Merlin N. J., Aiswarya Nair, Shaiju Dharan, ...
Assessment of Drinking Water Quality in Sambalpur Municipality Area, Odisha, Ind...
Preetam Kumar Senapati, Pabitra Mohan Behera, ...
View more
Download PDF
Related Articles
Advances in Small Molecule Inhibitors for Cancer Inflammation and Autoimmune Dis...
Aditi Jyotishi, Roshani Bhavsar, Roshani Bhavsar, Ashvini Patmase, Shubham Ahir, Kamran Ahmad Shaikh...
Implantable Drug Delivery System...
Divekar Payal, Shinde Kiran, ...
A Review on Herbal Face Pack for Glowing Skin ...
Shivprasad Gholap , Vikas Cholke , Sakshi Dethe, Snehal Mhase, ...
Laxative Agents: A Comprehensive Review of Mechanisms, Sources, and Clinical Imp...
Amit Tripathi, Dhiraj Kumar, ...
A Comprehensive Review on Pharmacist Contributions and Challenges in Disease Pre...
Dr. Sphurthymitra, P. Naga Sruthi, ...
More related articles
A Comprehensive Review on Pharmacist Contributions and Challenges in Disease Pre...
Dr. Sphurthymitra, P. Naga Sruthi, ...
Promoting Green Chemistry in Analysis: An Assessment of Analytical Methodologies...
Umaparvathy S., Karunya B., Sakthivel S., Manikandan R., Gokula Suruthi S., Thenkuzhali R., ...
A Review of the Latest Breakthroughs in Cancer Treatment, Including Targeted The...
Vikas Rathod, Swapnil Kale, Sneha Kanase , Shraddha Shelke, Aditya Wandhare , Sarthak Dungarwal , Ak...
View more
A Comprehensive Review on Pharmacist Contributions and Challenges in Disease Pre...
Dr. Sphurthymitra, P. Naga Sruthi, ...
Promoting Green Chemistry in Analysis: An Assessment of Analytical Methodologies...
Umaparvathy S., Karunya B., Sakthivel S., Manikandan R., Gokula Suruthi S., Thenkuzhali R., ...
A Review of the Latest Breakthroughs in Cancer Treatment, Including Targeted The...
Vikas Rathod, Swapnil Kale, Sneha Kanase , Shraddha Shelke, Aditya Wandhare , Sarthak Dungarwal , Ak...
View more

Copyright © 2025 IJPS. All rights reserved